
    
      Prospectively evaluate the safety and effectiveness of CD19/CD22 dual-target CAR-T cells in
      the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Strictly follow the
      inclusion criteria to screen eligible subjects for inclusion in clinical trials. The selected
      patients received CD19/CD22 dual-target CAR-T cell therapy. After the treatment is over,
      follow-up regularly to determine the survival status and follow-up treatment.
    
  